Q-omics provides the consensus-scored UGT1A12P profile across patient tissues and cancer cell-line models. UGT1A12P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, UGT1A12P is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, UGT1A12P RNA expression shows 5,681 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, and STAD as cancer lineages where UGT1A12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGT1A12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGT1A12P survival associations across molecular data types. UGT1A12P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGT1A12P RNA expression–survival associations across cancer types. High UGT1A12P expression shows unfavorable associations in UVM, KICH, KIRC, MESO, COAD and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for UGT1A12P RNA expression.
This table summarizes UGT1A12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for UGT1A12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGT1A12P shows higher tumor expression in STAD, COAD and LIHC. The STAD box plot shows higher UGT1A12P RNA expression in tumor versus normal tissue (log2 FC = +0.355, t-test p = .004).
This table shows molecular features associated with UGT1A12P in patient tissues and cancer cell lines. In patient samples, UGT1A12P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
